Recro Pharma Inc. (REPH) 6.31 $REPH
Recro Pharma Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 6:30AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the first quarter ended March 31, 2014.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Recro Pharma Announces New Board Members
GlobeNewswire - Thu Mar 13, 12:24PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for post-operative pain, today announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the Company's Board of Directors.
Recro Pharma Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 3:13PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the closing of its previously announced initial public offering of 3,750,000 shares of common stock at a public offering price of $8.00 per share. In connection with this offering, the underwriters exercised in full their option to purchase an additional 562,500 shares of common stock from the company. Total gross proceeds from the offering were $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.
Recro Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 562,500 shares of common stock at a public offering price of $8.00 per share, in connection with the company's recently announced initial public offering of 3,750,000 common shares. The full exercise of the option brings total gross proceeds from the offering to $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Recro Pharma Announces Pricing of Its Initial Public Offering
GlobeNewswire - Fri Mar 07, 3:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the pricing of its initial public offering of 3,750,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds to Recro Pharma from the initial public offering are expected to be $30,000,000 before underwriting discounts and commissions and estimated offering expenses. Recro Pharma has granted the representative of the underwriters a 45 day option to purchase up to 562,500 additional shares of common stock from the Company to cover over-allotments, if any. Shares of Recro Pharma's common stock have been approved for listing on the NASDAQ Capital Market under the symbol "REPH" and are expected to begin trading on March 7, 2014.
Recro Pharma Reports First Quarter 2014 Financial Results
GlobeNewswire - Mon May 12, 6:30AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the first quarter ended March 31, 2014.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 23, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Recro Pharma Announces New Board Members
GlobeNewswire - Thu Mar 13, 12:24PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for post-operative pain, today announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the Company's Board of Directors.
Recro Pharma Announces Closing of Initial Public Offering
GlobeNewswire - Wed Mar 12, 3:13PM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the closing of its previously announced initial public offering of 3,750,000 shares of common stock at a public offering price of $8.00 per share. In connection with this offering, the underwriters exercised in full their option to purchase an additional 562,500 shares of common stock from the company. Total gross proceeds from the offering were $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.
Recro Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 562,500 shares of common stock at a public offering price of $8.00 per share, in connection with the company's recently announced initial public offering of 3,750,000 common shares. The full exercise of the option brings total gross proceeds from the offering to $34,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the company.
Coupons.com IPO A Hot Ticket, Soars 88% On First Day
at Investor's Business Daily - Fri Mar 07, 11:24AM CST
Coupons.com (COUP) cashed in a winning ticket Friday with an initial public offering that nearly doubled on its first day of trading. The website provider of digital coupons priced at $16, above the proposed range of $12 to $14. The stock opened at...
Recro Pharma Announces Pricing of Its Initial Public Offering
GlobeNewswire - Fri Mar 07, 3:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, today announced the pricing of its initial public offering of 3,750,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds to Recro Pharma from the initial public offering are expected to be $30,000,000 before underwriting discounts and commissions and estimated offering expenses. Recro Pharma has granted the representative of the underwriters a 45 day option to purchase up to 562,500 additional shares of common stock from the Company to cover over-allotments, if any. Shares of Recro Pharma's common stock have been approved for listing on the NASDAQ Capital Market under the symbol "REPH" and are expected to begin trading on March 7, 2014.
